CN110437145A - 酪氨酸激酶抑制剂及其应用 - Google Patents
酪氨酸激酶抑制剂及其应用 Download PDFInfo
- Publication number
- CN110437145A CN110437145A CN201910822704.XA CN201910822704A CN110437145A CN 110437145 A CN110437145 A CN 110437145A CN 201910822704 A CN201910822704 A CN 201910822704A CN 110437145 A CN110437145 A CN 110437145A
- Authority
- CN
- China
- Prior art keywords
- compound
- cancer
- washing
- tyrosine kinase
- organic phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910822704.XA CN110437145A (zh) | 2016-09-13 | 2016-09-13 | 酪氨酸激酶抑制剂及其应用 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910822704.XA CN110437145A (zh) | 2016-09-13 | 2016-09-13 | 酪氨酸激酶抑制剂及其应用 |
| CN201610822529.0A CN107235896B (zh) | 2016-09-13 | 2016-09-13 | 酪氨酸激酶抑制剂及其应用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610822529.0A Division CN107235896B (zh) | 2016-09-13 | 2016-09-13 | 酪氨酸激酶抑制剂及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110437145A true CN110437145A (zh) | 2019-11-12 |
Family
ID=59982910
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910822704.XA Pending CN110437145A (zh) | 2016-09-13 | 2016-09-13 | 酪氨酸激酶抑制剂及其应用 |
| CN201610822529.0A Active CN107235896B (zh) | 2016-09-13 | 2016-09-13 | 酪氨酸激酶抑制剂及其应用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610822529.0A Active CN107235896B (zh) | 2016-09-13 | 2016-09-13 | 酪氨酸激酶抑制剂及其应用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10882853B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3511327B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7487921B2 (cg-RX-API-DMAC10.html) |
| KR (2) | KR20190045354A (cg-RX-API-DMAC10.html) |
| CN (2) | CN110437145A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2017325641B2 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2902549T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018049861A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3655406A1 (en) | 2017-07-18 | 2020-05-27 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| SG11202006945PA (en) | 2018-01-26 | 2020-08-28 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| AU2019212800B2 (en) | 2018-01-26 | 2024-05-23 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| AR119069A1 (es) * | 2019-06-04 | 2021-11-24 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de quinasas |
| CN112358469A (zh) * | 2020-03-18 | 2021-02-12 | 北京康辰药业股份有限公司 | 血管生成抑制剂、其制备方法及其应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005030140A2 (en) * | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and methods of use |
| CN105001168A (zh) * | 2015-08-25 | 2015-10-28 | 佛山市赛维斯医药科技有限公司 | 三烷氧基取代的苯并喹唑啉类酪氨酸激酶抑制剂及其用途 |
| CN105017163A (zh) * | 2015-08-25 | 2015-11-04 | 佛山市赛维斯医药科技有限公司 | 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途 |
| CN105085416A (zh) * | 2015-08-25 | 2015-11-25 | 佛山市赛维斯医药科技有限公司 | 一类硝基取代的双烷氧苯并喹唑啉类酪氨酸激酶抑制剂及用途 |
| CN105218445A (zh) * | 2015-08-25 | 2016-01-06 | 江苏中邦制药有限公司 | 一种络氨酸酶抑制剂Foretinib的制备方法 |
| CN105884695A (zh) * | 2015-02-13 | 2016-08-24 | 山东轩竹医药科技有限公司 | 杂环衍生物类酪氨酸激酶抑制剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| AU2009303602B2 (en) * | 2008-10-14 | 2012-06-14 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
| EP2408300B1 (en) * | 2009-03-21 | 2016-05-11 | Sunshine Lake Pharma Co., Ltd. | Amino ester derivatives, salts thereof and methods of use |
| US8664244B2 (en) | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| CN104817497B (zh) * | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
-
2016
- 2016-09-13 CN CN201910822704.XA patent/CN110437145A/zh active Pending
- 2016-09-13 CN CN201610822529.0A patent/CN107235896B/zh active Active
-
2017
- 2017-06-22 JP JP2019515307A patent/JP7487921B2/ja active Active
- 2017-06-22 AU AU2017325641A patent/AU2017325641B2/en not_active Ceased
- 2017-06-22 EP EP17850066.6A patent/EP3511327B1/en not_active Not-in-force
- 2017-06-22 KR KR1020197010451A patent/KR20190045354A/ko not_active Ceased
- 2017-06-22 US US16/333,050 patent/US10882853B2/en active Active
- 2017-06-22 WO PCT/CN2017/089501 patent/WO2018049861A1/zh not_active Ceased
- 2017-06-22 ES ES17850066T patent/ES2902549T3/es active Active
- 2017-06-22 KR KR1020217037589A patent/KR102382039B1/ko active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005030140A2 (en) * | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and methods of use |
| CN105884695A (zh) * | 2015-02-13 | 2016-08-24 | 山东轩竹医药科技有限公司 | 杂环衍生物类酪氨酸激酶抑制剂 |
| CN105001168A (zh) * | 2015-08-25 | 2015-10-28 | 佛山市赛维斯医药科技有限公司 | 三烷氧基取代的苯并喹唑啉类酪氨酸激酶抑制剂及其用途 |
| CN105017163A (zh) * | 2015-08-25 | 2015-11-04 | 佛山市赛维斯医药科技有限公司 | 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途 |
| CN105085416A (zh) * | 2015-08-25 | 2015-11-25 | 佛山市赛维斯医药科技有限公司 | 一类硝基取代的双烷氧苯并喹唑啉类酪氨酸激酶抑制剂及用途 |
| CN105218445A (zh) * | 2015-08-25 | 2016-01-06 | 江苏中邦制药有限公司 | 一种络氨酸酶抑制剂Foretinib的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102382039B1 (ko) | 2022-04-01 |
| US10882853B2 (en) | 2021-01-05 |
| ES2902549T3 (es) | 2022-03-28 |
| EP3511327A4 (en) | 2019-08-07 |
| EP3511327B1 (en) | 2021-10-27 |
| WO2018049861A1 (zh) | 2018-03-22 |
| EP3511327A1 (en) | 2019-07-17 |
| KR20190045354A (ko) | 2019-05-02 |
| CN107235896B (zh) | 2019-11-05 |
| US20190248772A1 (en) | 2019-08-15 |
| JP7487921B2 (ja) | 2024-05-21 |
| CN107235896A (zh) | 2017-10-10 |
| AU2017325641A1 (en) | 2019-04-11 |
| AU2017325641B2 (en) | 2021-08-26 |
| KR20210143935A (ko) | 2021-11-29 |
| JP2019529435A (ja) | 2019-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107235896B (zh) | 酪氨酸激酶抑制剂及其应用 | |
| CN105263326B (zh) | 甲基/氟-吡啶基-甲氧基取代的吡啶酮-吡啶基化合物及氟-嘧啶基-甲氧基取代的吡啶酮-吡啶基化合物 | |
| KR102698366B1 (ko) | 피라졸 피리미딘 유도체 및 이의 용도 | |
| CN106536503B (zh) | 一种酪氨酸激酶抑制剂及其用途 | |
| CN108976172B (zh) | 一类4-嘧啶二胺类小分子有机化合物及其衍生物及其应用 | |
| KR20210065097A (ko) | 치환된 인돌 및 이의 사용 방법 | |
| KR20230065261A (ko) | 자가면역질환 및 암 치료용 저분자 화합물 | |
| JP2022504541A (ja) | 低分子mdm2タンパク質デグレーダー | |
| WO2012041524A1 (en) | Hydrazonopyrazolones as protein tyrosine phosphatase inhibitors | |
| Zhang et al. | Discovery and evaluation of triple inhibitors of VEGFR-2, TIE-2 and EphB4 as anti-angiogenic and anti-cancer agents | |
| CN109776607B (zh) | 芳基磷氧类和芳基磷硫类化合物及其制备方法和应用 | |
| WO2019024876A1 (zh) | 一种具有fgfr4抑制活性的醛基吡啶衍生物、其制备方法和应用 | |
| CN110577546B (zh) | Vegfr抑制剂及其制备方法和应用 | |
| CN113387957A (zh) | 螺环吲哚酮-吡咯烷碳酸酯化合物和其组合物、制备方法及用途 | |
| TWI546304B (zh) | Protein tyrosine kinase inhibitors and their use | |
| CN108794398B (zh) | 具有荧光的选择性组蛋白去乙酰化酶抑制剂及其制备方法和应用 | |
| CN107235897B (zh) | 酪氨酸激酶抑制剂及其应用 | |
| WO2023168740A1 (zh) | 喹啉类化合物的新用途 | |
| CN118724825B (zh) | 一种Mer/HDAC双靶点抑制剂及其在制备抗肿瘤药物中的应用 | |
| CN118515623B (zh) | 一种取代苯并异恶唑类化合物及其在制备抗肿瘤药物中的应用 | |
| CN117466889B (zh) | 一种1H-吡咯[2,3-b]吡啶化合物及其合成方法和应用 | |
| JP6541635B2 (ja) | Parp阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン | |
| EA049962B1 (ru) | Новые соединения, применяемые в качестве ингибиторов поли(адф-рибоза)полимеразы (parp) | |
| CN104311494A (zh) | 间-(4-吗啉基-2-喹唑啉基)苯甲酰胺类化合物及其合成方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200430 Address after: 200082 floor 3, building 1, No. 400, Fangchun Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai Applicant after: Lixin Pharmaceutical Technology (Shanghai) Co.,Ltd. Address before: 201913 room 543, building a, 2528 Panyuan Road, Changxing Town, Chongming County, Chongming District, Shanghai Applicant before: Shanghai Xiangjin Biotechnology Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191112 |
|
| WD01 | Invention patent application deemed withdrawn after publication |